PCSA · Processa Pharmaceuticals, Inc.
The latest filing states the doubt was alleviated.
“Following our acquisition of Vidya and closing of the related $200 million gross private placement (from which we received net proceeds of $183.3 million) on July 30, 2026, we believe our cash and cash equivalents will be sufficient to satisfy our cash requirements over the next 12 months and beyond. This represents a material change from what we reported in our 2025 Form 10-K that disclosed substantial doubt of our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Dec 17, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Dec 17, 2025.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PCSA
this stock
Processa Pharmaceuticals, Inc.
|
$5.56M | -30.9% | -95.6% | — | 2.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.08B | +14.9% | +46.2% | 30.4 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.15B | +4.6% | +20.8% | 20.0 | 2.3% |
|
ARGX
Argenx SE
|
$62.63B | +19.2% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.54B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Dec 17, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PCSA | -2.9% | -24.3% | -37.0% | -2.9% | -30.9% |
| SPY | +0.1% | -1.1% | +15.3% | -0.6% | +11.8% |
| vs SPY | -3.0% | -23.3% | -52.3% | -2.3% | -42.7% |